ONS Annual Congress Heralds Start of Oncology Nursing Month

ONS Annual Congress Heralds Start of Oncology Nursing Month

April 1, 2006

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 15 No 4

Volume 15

Issue 4

The Oncology Nursing Society (ONS) Board of Directors has announced the 12th Annual Oncology Nursing Day and Month celebration to recognize oncology nurses and to increase awareness of the specialty.

PITTSBURGHThe Oncology Nursing Society (ONS) Board of Directors has announced the 12th Annual Oncology Nursing Day and Month celebration to recognize oncology nurses and to increase awareness of the specialty. The celebration kicks off on Thursday, May 4, 2006, on Oncology Nursing Day, during the Opening Ceremony of the Society's 31st Annual Congress in Boston, Massachusetts, and continues until May 31, 2006.

Oncology Nursing Month has been designed to recognize oncology nurses, to educate the public about oncology nursing, to provide an opportunity for special educational events for oncology nurses, and to celebrate the accomplishments of oncology nurses. A brochure with tips on how to promote Oncology Nursing Month is available on the Society's website at www.ons.org.

Look for comprehensive coverage of oral presentations, lectures, and posters from the Society's 31st Annual Congress in upcoming issues of ONI.

Articles in this issue

Phase II Trial of Velcade/Alimta Initiated in Advanced NSCLC

ONS Annual Congress Heralds Start of Oncology Nursing Month

All-Star Panel Spells Out Onc Promises, Problems

Surveillance for Colon, Breast Ca Falls Off 5 Years After Diagnosis

ODAC Says No to Gemzar for Ovarian Ca

Experts See Oncology Reimbursements Headed Down, Hard Negotiations With Payers Lie Ahead

Femara Effective Even After Years of No Therapy

XMRV Retrovirus Found in Some Prostate Ca's

Taxotere Wins FDA Approval for Advanced Gastric Cancer

Community Oncology Practices Struggle to Cope With the Extra Requirements of Medicare Part D

Director of NCI Nominated as New FDA Commissioner

TAM-01 Finds Longer Tamoxifen Duration Is Not Better

Erbitux Wins Approval for Squamous Cell H&N Cancer

Young Doctors Are Hungry for Psychological Oncology Training

Posaconazole Reduces Serious IFIs in High-Risk Patients

Related Content

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer

April 19th 2024

Article

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024

Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers

April 19th 2024

Article

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024

Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

FDA Approves Alectinib for Early-Stage ALK+ NSCLC

April 18th 2024

Article

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.